Sodium-Glucose Transporters as a Therapeutic Target for Diabetes from the Viewpoint of Drug Discovery and Pharmacotherapy

DOI Web Site Web Site PubMed 10 References Open Access
  • Miyamoto Licht
    Department of Medical Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School
  • Tsuchiya Koichiro
    Department of Medical Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School

Bibliographic Information

Other Title
  • 創薬と薬物治療から見た糖尿病治療標的としてのSGLT
  • Symposium Review 創薬と薬物治療から見た糖尿病治療標的としてのSGLT
  • Symposium Review ソウヤク ト ヤクブツ チリョウ カラ ミタ トウニョウビョウ チリョウ ヒョウテキ ト シテ ノ SGLT

Search this article

Abstract

　Sodium-glucose transporter (SGLT)-2 inhibitors, which are currently in clinical use in most of the world, are unique as their hypoglycemic effects are completely independent of insulin action. Potential benefits and indications for the treatment of other diseases like circulatory and renal disorders are attracting attention. SGLT2 inhibitors not only reduce blood glucose levels but also alter the whole-body energy balance to lower body weight, which should result in the amelioration of multiple metabolic disorders like metabolic syndrome. In the symposium, we briefly introduced the physiological as well as biological functions of SGLTs and discussed strategies for drug design by looking back at the history of drug discovery for SGLT2 inhibitors. We also shared our recent data on their combined usage with other hypoglycemic agents and effects on glucagon secretion, which are current clinical topics relevant to SGLT2 inhibitors. Among those topics, strategies for drug discovery of SGLT2 inhibitors are discussed in this review.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 138 (7), 933-938, 2018-07-01

    The Pharmaceutical Society of Japan

References(10)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top